SCHEMBL3480342

SCHEMBL3480342

O=P(O)(O)CNS(=O)(=O)c1cnc(-c2ccc(O)c(O)c2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 8/20 0.46
MAPT P10636 1/20 0.33
PKLR P30613 1/20 0.32
HSD17B1 P14061 3/20 0.32
HSD17B2 P37059 3/20 0.32
PRKAB2 O43741 1/20 0.32
LCK P06239 1/20 0.32
SRC P12931 1/20 0.32
FLT1 P17948 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32
PRKAG1 P54619 1/20 0.32
PRKAA2 P54646 1/20 0.32
PRKAA1 Q13131 1/20 0.32
RPS6KA1 Q15418 1/20 0.32
MKNK1 Q9BUB5 1/20 0.32
PRKAG3 Q9UGI9 1/20 0.32
PRKAG2 Q9UGJ0 1/20 0.32
PRKAB1 Q9Y478 1/20 0.32
FDPS P14324 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3480546 0.82 KDM4E (0.41) MAPT
SCHEMBL3480489 0.79 SNCA (0.47) SNCAMAPTPKLRHSD17B1HSD17B2
SCHEMBL3480486 0.78 HSD17B13 (0.32) HSD17B13
SCHEMBL3480182 0.69 GAA (0.40)
SCHEMBL3480445 0.68 SERPINE1 (0.38) SERPINE1
SCHEMBL12682347 0.65 SNCA (0.69) SNCAMAPTHSD17B1HSD17B2
SCHEMBL3480434 0.65 MMP13 (0.45) MKNK1
SCHEMBL13032502 0.64 SNCA (0.65) SNCAMAPTHSD17B1HSD17B2GUSB
SCHEMBL12498385 0.64 SNCA (1.00) SNCAMAPTHSD17B1HSD17B2GUSB
SCHEMBL4427998 0.64 SMN1; SMN2 (0.55) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US claimed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP claimed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO claimed
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 US disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 EP disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MGAM, BPGM, PPME1 SNCA 2555/4885MAPT 4576/4885PKLR 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.